REMEHIP a multicenter registry began in 2015 with a planned recruitment time of 12 months and a 4-year follow-up. The study population will comprise a longitudinal cohort study, collecting data on patients with prevalent and incident pulmonary hypertension. Will be included patients of age >2 years and diagnosis of pulmonary hypertension by right heart catheterization within Group 1 and Group 4 of the World Health Organization classification. The structure, data collection and data analysis will be based on quality current recommendations for registries. The protocol has been approved by institutional ethics committees in all participant centers. All patients will sign an informed consent form. Currently in Mexico, there is a need of observational registries that include patients with treatment in the everyday clinical practice so the data could be validated and additional information could be obtained versus the one from the clinical trials. In this way, REMEHIP emerges as a link among randomized clinical trials developed by experts and previous Mexican experience.
A189 analyzed for 365 days after and before the accrual period. RESULTS: On a total of 2,962,498 subjects observed, 594 patients were hospitalized for melanoma (53.4% males) during 2009 (prevalence rate: 20.0 per 100,000). Among them, 43% had at least one chronic comorbidity, hypertension is the most common (14.6%) followed by combination of dyslipidemia and hypertension (3.0%). Therapy for melanoma is made both in and outside the hospital. Interferon alfa-2b was the most prescribed treatment outside the hospital with an average cost of €110, followed by Temozolomide (€40.7) and Erythropoietin (€39.6). During one-year of follow-up, 13% of patients was hospitalized for chemotherapy with an average cost of €7398. This amount covers also drug treatment cost during hospitalization. The average yearly cost/patient for population with melanoma was €4777 (hospitalizations: 70.8%, drugs: 14.4%, diagnostic examinations: 14.8%), with an higher cost for the subgroup of patient already in treatment the previous year before the accrual period (€6156 vs €4361). If we consider the subgroup of patient with metastatic melanoma (N=176), the overall cost rises at €15,984, most of it (60%) due to drug costs for specific therapy of melanoma and chemotherapy. Surprisingly methotrexate and cyclophosphamide appear in the top five list of prescribed drugs. CONCLUSIONS: This study shows high cost of patients with melanoma and how real world practice therapy, especially for metastatic melanoma, seems to be far from the guidelines recommendation. This suggests to create a regional network to correctly redirect therapeutic choices.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.